Important Safety Information
Orforglipron oral tablet
Boxed Warning
Orforglipron, like other GLP-1 receptor agonists, has shown thyroid C-cell tumors in rodent studies at clinically relevant exposures. It is unknown whether orforglipron causes such tumors, including medullary thyroid carcinoma, in humans. Foundayo is contraindicated in patients with a personal or family history of MTC and in patients with MEN 2.
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist indicated for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity.
Orforglipron may cause serious side effects, including:
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to the manufacturer or to your NowYou care team.
This summary does not include all information about this medication. It is not a substitute for the full Prescribing Information or for talking with your healthcare provider. Please read the full Prescribing Information and Medication Guide before starting treatment, and discuss any questions with your provider.
This safety summary is provided for educational purposes and does not replace the full Prescribing Information, Medication Guide, or professional medical advice. Always discuss benefits, risks, and alternatives with your licensed provider.